TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Pain Score as measured by Pain Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Status as measured by EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Achieving Six Month Seizure Freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of post inflammatory hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Freezing of Gait Questionnaire (FOGQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DNA damage in WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant activity in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine disability assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage Change In Convulsive Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quadriceps Muscle Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening model of COPD combined with OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prognosis model of COPD combined with OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Health-Related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: retinal blood vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of venous thrombosis and pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of laryngospasm with apnea
Endpoint domain: Adverse events/effects
Primary endpoint: Blood oxygen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of desensitizers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute walk test (6MWT) distance completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle volume and thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in quadriceps muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in exercise-induced markers of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events with score ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Recurrence of Active Intermediate, Posterior, or Panuveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulsatility index in fetal vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local Control Rate (LCR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control Rate (LCR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control Rate (LCR) at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence density of catheter-related bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare utilisation: Primary care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healthcare utilisation: Inpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healthcare utilisation: Specialist outpatient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healthcare utilisation: A&E
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient-reported outcome measure for patient activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported outcome measure for quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sacral slope between standing to sitting difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of type 1 pelvic kinematic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration of Abdominal Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bergen insomnia scale (BIS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: latency of reflex muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of re-hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Attitudes regarding the benefits and barriers to using sunless tanning products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of a beach-based pilot intervention (sun exposure at 2-, and 12- months follow-up)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Global Health-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Fractional Anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stimulation Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Electrical muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance to movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Team confidence around tube placement at the time of tube placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom From MAEs Within 30 Days of Index Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in lab safety tests
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in ECGs, vital signs and PE findings
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of top-up transfusions required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-care self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with plasma HCV RNA levels below 15 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lack of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of acromegaly patients classified using SAGIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norelgestromin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Ethinyl Estradiol and Norelgestromin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Over a Dosing Interval (AUCτ) of Ethinyl Estradiol and Norelgestromin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of tasocitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of tasocitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tasocitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in GERD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean lactate/pyruvate conversion rate (kPL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean lactate-to-pyruvate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term changes in general mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knowledge Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of conservatively treated ventral hernias that undergo surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: D-dimer profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Severe Adverse Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional Shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional status one year after diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of belinostat plus bortezomib
Endpoint domain: Adverse events/effects
Primary endpoint: Indexed Left Ventricular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of methoxyamine
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicities of the combination of methoxyamine and temozolomide
Endpoint domain: Adverse events/effects
Primary endpoint: Sepsis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in ocular surface staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Preference for therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality related to aneurysm
Endpoint domain: Mortality/survival
Primary endpoint: GCF level of protein carbonyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Capsular Contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual analog scale of pain in feet during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intra-abdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Short Physical Performance Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Usual walking speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Four Step Square Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients alive at postoperative 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Patients discharged alive from the hospital in unassisted breathing before 60 days
Endpoint domain: Mortality/survival
Primary endpoint: exosome levels in cancer tissue and para cancerous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement concerning the risk of difficult intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Flavoprotein fluorescence index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tegner Activity Level Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in global longitudinal strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraviginal ejaculation latency time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement on post-PCI fractional flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate to treatment with gefitinib alone for 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to treatment with gefitinib in combination with PEG-interferon alfa-2a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of rash after treatment with gefitinib for 1 month and after the addition of PEG-interferon alfa-2a to gefitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: mean overall colon cleansing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and severity of nail and skin toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative variation of cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Condition of the Peri Wound Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resting-state functional connectivity with ventral striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resting-state functional connectivity with dorsal striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive flexibility task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Readmission ratio
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Appropriate management for VTE prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Conners' Global Index - Parent Version (CGI-P)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conners' Global Index - Teacher Version (CGI-T)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-harm Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of adherence to treatment by patients and by professionals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of appropriateness of the treatment according to previous professional training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment direct costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Correct detection of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response to steroid treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successfully created ports and their closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in concentrations of biomarkers of vitamin B12 in mother-child pairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaccine specific immunity in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive, Language and Motor Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nuroinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV seroprevalence of adolescents and young adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: anti-influenza systemic and mucosal antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in JRS Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in JRS Frequency Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Sustained Forced Eye Blinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Duration of Forced Blinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of Suicidality
Endpoint domain: Adverse events/effects
Primary endpoint: Global efficacy evaluations
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fat free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neural activity to threat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Clinical Benefit (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of buprenorphine and naloxone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overt Aggression Scale-Modified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions-Improvement Item
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Losartan concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Research Council (MRC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Guy's Neurological Disability Scale (GDNS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuropathic symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Grade 3 or 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with abnormal blood pressure, heart rate, body temperature, and/or physical examination that are related to the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Inflammatory Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak oxygen uptake (VO2 peak, ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COVID-19 severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of SARS-Cov-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure (GMFM-88)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 min walk Test (2MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral Follicle Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Peak average of pelvic floor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative atelectasis
Endpoint domain: Adverse events/effects
Primary endpoint: Insertion and removal characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meningococcal rSBA titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-meningococcal polysaccharide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of serious adverse events related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of Tube Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: occurrence of spontaneous bacterial peritonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return to normal sinus rhythm (NSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration-time Curve for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes